Insightec Ltd. Overview
Pro stress-test →Insightec is a provider of MR-interfaced ultrasound technology-based devices for cancer and neurology. The company's Exablate Neuro platform focuses on sound waves guided by MRI to treat patients with medication-refractory essential tremor, Parkinson's Disease, uterine fibroids, and pain palliation of metastatic bone. The company operates as a well-funded innovator in precision, non-invasive therapeutic solutions.
Strategic Profile
Pro stress-test →Insightec specializes in non-invasive, precision treatments for movement disorders. The company secured $150M in June 2024, bringing total funding to over $800M, positioning it as a leader in MR-guided focused ultrasound therapy. Strategic partnerships and expanding global reach, including Health Canada approval for the Exablate Prime System in March 2026 and national reimbursement in France for essential tremor treatment in March 2026, support continued market expansion.
Competitive Landscape
Pro stress-test →Competitors include CVRx, Spine Wave, Nevro, HistoSonics, and Carmat. Insightec maintains a strong competitive moat through proprietary MRI-guided ultrasound technology, extensive clinical data, and growing global regulatory approvals. The company's focus on both neurology (tremor, Parkinson's) and oncology differentiate it from narrower competitors.
Industry Context
Insightec Ltd. operates in Therapeutic ultrasound devices.
Key facts
Founded: 1999 · Headquarters: Tirat Carmel, Israel · Employees: 522 · Revenue: $100.3M